Ialugen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ialugen

Quick Facts

Property Description
Active ingredient Sodium Hyaluronate (Hyaluronic Acid sodium salt)
Form Topical Cream, Medicated Gauze (Dressing)
Pharmacological class Tissue Regenerator, Wound Healing Agent
Common use Supporting epithelial repair and skin integrity restoration
Origin Naturally derived polysaccharide

What Type of Medicine is Ialugen? (Classification and Forms)

Ialugen is a specialized dermatological agent and wound healing agent broadly classified as a Tissue Regenerator. This medicinal preparation is exclusively intended for direct application to the skin surface, with its route of administration being strictly topical. Ialugen is commonly supplied as a topical cream or as a sterile medicated gauze (dressing), providing flexible dosage form(s) suitable for managing various dermal lesions. This classification is clinically recognized, reflecting its active role in supporting the biological processes essential for efficient skin renewal.

Composition: Sodium Hyaluronate, A Naturally Derived Active Substance

The primary active ingredient in Ialugen is Sodium Hyaluronate (INN: Hyaluronate sodium), the highly soluble sodium salt of Hyaluronic Acid (Hyaluronan). This compound is classified as a naturally derived polysaccharide, an essential component of the extracellular matrix of human tissues. The distinct characteristic of using this specific salt form ensures stability and consistent therapeutic activity in the topical base. As a component integral to connective tissues, hyaluronate assists with cell migration, which is vital for healing. While Ialugen is typically a Single-ingredient product, its product line may include Combination products—such as Ialugen Plus—which contain supplementary active agents.

General Purpose: Supporting Epithelial Repair and Skin Integrity

The general therapeutic purpose of Ialugen is to facilitate and accelerate the body's natural process of epithelial repair and skin integrity restoration following damage. It supports the optimal healing environment by leveraging the high hydration and viscoelastic properties of Sodium Hyaluronate to maintain necessary wound moisture. Hyaluronic acid plays a functional role in supporting tissue matrix structure during wound repair, reflecting its regenerative capacity. This structural support ensures the wound heals efficiently and contributes to the proper organization of new tissue.

Regulatory References

  1. EMA Cutaneous Products Guideline

What side effects are possible with Ialugen?

Possible Side Effects and Safety Information

The safety profile for Ialugen (Sodium Hyaluronate) and its combination product, often containing Silver Sulfadiazine, is formally documented in government regulatory labeling. Adverse reactions are classified by frequency and body system affected.

Frequency-Classified Adverse Reactions

The most commonly reported adverse effects are localized, relating to the application site. Systemic effects, primarily tied to the sulfonamide component's potential for absorption, are documented in official prescribing information.

Classification Examples of Officially Documented Adverse Reactions
Common Leukopenia (decreased white blood cell count), pruritus, rash, contact dermatitis, eczema
Rare Argyria (localized skin discoloration)

System-Organ Classes and Serious Risks

Adverse effects are categorized into System-Organ Classes (SOCs), with most risks falling under Skin and Subcutaneous Tissue Disorders and Blood and Lymphatic System Disorders.

Serious Adverse Reactions are rare but officially documented and include severe dermatological conditions such as Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN). Other serious risks include Agranulocytosis, Aplastic Anemia, and organ toxicities like Renal or Hepatocellular failure.

Population-Specific Safety Constraints

Official labels impose strict safety constraints for certain patient populations:

  • Neonates/Infants: The product is contraindicated in premature babies and newborn infants up to two months of age due to the risk of kernicterus.
  • Pregnancy: Avoidance is recommended during the third trimester due to potential risk of neonatal jaundice.
  • Pre-existing Conditions: Caution is advised for patients with severe renal or hepatic impairment or Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Exposure- and Duration-Related Safety Notes

The regulatory profile specifies that the likelihood of systemic adverse effects increases with prolonged use or application over a large surface area due to increased sulfonamide absorption.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile is related to the potential systemic absorption of the sulfonamide component when the preparation is applied to extensive skin surfaces or severely damaged tissue. This classification establishes the risk profile based on high-level absorption.

Documented Manifestations and Outcomes

Overdose resulting from high systemic absorption may lead to clinical signs consistent with systemic sulfonamide administration. Documented manifestations include hematologic effects such as leukopenia and severe outcomes like agranulocytosis or aplastic anemia. Hepatic and renal systems can also be affected, potentially presenting as jaundice or crystalluria. Life-threatening blood dyscrasias are documented regulatory concerns. Susceptible populations include patients with pre-existing impaired renal or hepatic function, who face an increased risk of drug accumulation. The preparation is officially contraindicated in newborns and premature infants due to the risk of kernicterus.

Emergency Actions and Management

Regulatory authorities state that immediate medical attention must be sought at the first sign of any adverse systemic reaction. If excessive topical quantity is used, patients are instructed to contact a Poison Control Center or emergency services immediately. No specific antidote is known. Management focuses on symptomatic and supportive treatment, which includes enhancing drug elimination through the urine, often with the use of bicarbonate liquid preparations. Careful monitoring of renal function and serum sulfa concentrations is required in high-exposure scenarios.

Therapeutic Uses of Ialugen

Quick Facts on Ialugen's Use

  • Helps manage various acute and chronic skin wounds.
  • Supports the process of wound healing and tissue repair.
  • Assists in addressing specific types of burns, pressure ulcers, and skin lesions.
  • Aids in preventing microbial contamination in the wound bed.

What Ialugen Treats: Main Uses and Benefits

Ialugen (Hyaluronic Acid/Silver Sulfadiazine) is an approved topical formulation primarily indicated for the management of various skin lesions and wounds. Its core purpose is to support the body's natural wound healing process, including for acute and chronic wounds.

The use of this combination assists in addressing conditions such as pressure ulcers (bedsores), venous ulcers, diabetic foot ulcers, and certain second-degree burns. By maintaining an appropriate environment, it promotes re-epithelialization, which is crucial for closing the wound.

Furthermore, the formulation helps in preventing microbial contamination and infection, which is a key factor in delayed healing. The combined components work to establish a favorable wound bed for tissue repair. This product is a widely utilized topical agent for managing complex wounds that require both healing support and microbial control.

It is utilized in the treatment of partial-thickness burns and other types of dermal injuries where healing is compromised.

Always consult with a qualified healthcare professional to determine if this preparation is appropriate for a specific clinical situation.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility Profile for Ialugen

Eligibility for Ialugen, particularly its combination product with silver sulfadiazine (Ialugen Plus), is strictly governed by regulatory classifications to minimize risk in vulnerable populations.

Absolute Contraindications (Must Not Use):

Category Regulatory Status
Hypersensitivity Contraindicated in patients allergic to hyaluronic acid, silver sulfadiazine, other sulfonamide drugs, or any excipient.
Infants Contraindicated in infants under two months of age due to the risk of kernicterus (sulfonamide-induced toxicity).
Maternal Status Contraindicated in women who are pregnant at term (near delivery) and in breastfeeding mothers for the same risk to the infant.

Restricted or Conditional Use:

Category Regulatory Status
Metabolic Status Use requires caution in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to risk of hemolysis.
Organ Function Caution is advised in patients with severe hepatic or renal impairment if the medicine is applied extensively, due to potential for systemic absorption.

Regulatory documents allow use in the general adult population and in children two months of age and older, provided no contraindications are present.

What should I know about interactions with other medicines?

The official interaction profile for products containing Sodium Hyaluronate and Silver Sulfadiazine is driven by chemical incompatibility and systemic effects from absorption.

A Topical Chemical Incompatibility exists for the Sodium Hyaluronate component. Quaternary Ammonium Salts (common disinfectants like benzalkonium chloride) must be avoided, as regulatory documents state these substances can cause the Sodium Hyaluronate to precipitate and become inactive.

For the Silver Sulfadiazine component, official labeling notes two main types of interactions. The silver content may cause Pharmacodynamic Inactivation of Topical Proteolytic Enzymes (e.g., collagenase, papain), making their concurrent use inappropriate.

Separately, due to the potential for systemic absorption on large wounds, the sulfonamide component can cause Systemic Drug Exposure Modification. This applies to highly protein-bound drugs, including Oral Anticoagulants and Phenytoin, whose effects may be potentiated. The effects of Oral Hypoglycemic Agents (sulfonylurea compounds) may also be enhanced.

Interaction risk is officially noted for specific patient populations. Individuals with Hepatic or Renal Impairment face an increased risk of drug accumulation. Additionally, use in G6PD-deficient patients is associated with the official caution of potential hemolysis.

Mechanism of Action

The mechanism of action of Ialugen is based on the combined local effects of its two active components, Hyaluronic Acid (HA) and Silver Sulfadiazine (SSD), which focus on modulating the local physiological environment. The HA component engages in Extracellular Matrix (ECM) organization. It functions as a structural component, binding water to maintain a moist microenvironment, and acts as a signaling molecule via cell receptors like CD44. This signaling encourages the migration and proliferation of keratinocytes and fibroblasts, leading to re-epithelialization and organization of new connective tissue. Concurrently, the SSD component provides Microbial Load Control. It releases silver ions ( Ag^+) which interfere with fundamental processes within microorganisms, including DNA replication and cell wall synthesis. This metabolic and structural disruption results in a reduced viable microbial concentration at the application site, which allows the progression of tissue repair.

Dosage and Administration Information

How to Use Ialugen (Sodium Hyaluronate)

These instructions outline the administration guidelines for Ialugen products (containing Sodium Hyaluronate) and Ialugen Plus (containing Sodium Hyaluronate and Silver Sulfadiazine). The medicine is for topical use only.

Procedural Administration Steps

  1. Preparation: The wound and its surrounding areas must be cleaned and disinfected prior to the application of the medicine. If cream residue remains from a previous application, it is recommended to remove it.
  2. Application:
    • Cream: Apply in a thin layer evenly over the entire affected area 2–3 times a day.
    • Medicated Gauzes: Apply one or more gauzes directly onto the wound, depending on the surface size, 2 or more times a day. The gauze must be covered with a sterile secondary dressing and secured with a bandage.

Special Instructions

Administration Element Description
Route Topical (External use only)
Duration Continue until satisfactory healing has occurred (e.g., formation of a scar).
Monitoring Consult a physician if the wound has not healed after 10–14 days.
Age Restriction Ialugen Plus is contraindicated in newborns and infants in the first two months of life (due to the Silver Sulfadiazine component).
Interaction Avoid use of Ialugen Plus with topical proteolytic enzymes, as the silver component may inactivate them.
Single Use Medicated gauze packages are for single use only.

The use protocol requires a multi-step sequence: mandatory wound preparation, adherence to a defined daily frequency, and treatment continuation tied directly to the achievement of healing, with mandatory medical consultation if improvement is delayed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ialugen


Evidence for Use in Chronic Venous Leg Ulcers

Research has examined the use of topical sodium hyaluronate in patients with chronic venous leg ulcers (VLUs). Studies conducted during periods of heightened symptom activity include Randomized Controlled Trials (RCTs) and Systematic Reviews. These investigations was studied in research exploring how symptoms change over time, primarily measuring the time observed for complete ulcer closure, as well as changes measured in the ulcer's surface area. Studies reported measurements observed in the change in wound size during short-term observation. However, when these findings were observed in comparisons against other advanced wound care dressings, the data show patterns related to healing rates that were sometimes inconsistent across different trials.


Evidence for Use in Acute Wounds and Dermal Injuries

Research has examined sodium hyaluronate in a variety of acute wounds and dermal injuries, including general trauma, post-surgical wounds, and first- and second-degree burns. These studies were evaluated in populations with acute changes, often observing responses over defined time intervals. The outcomes related to physical discomfort that were measured included the time observed for re-epithelialization and the overall progression of healing. Because many of these trials are open-label or non-comparative, the comparative evidence is lacking against a wide array of other standard wound care products.


Gaps and Uncertainty in the Ialugen Research Record

The overall evidence landscape has several gaps and areas where certainty remains low. The comparative evidence is lacking in several areas, particularly against the full range of modern, sophisticated dressings available today. Furthermore, because sample sizes were modest in many trials, the evidence is constrained regarding how broadly the findings may apply. Follow-up durations were limited in most key trials, meaning long-term outcomes are not fully established regarding durability or recurrence. The research primarily describes group patterns for the populations that were specifically included, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Ialugen (FAQ)


Q: Is Ialugen available without a prescription in most places?

According to official packaging and regulatory status in some regions, Ialugen Cream and Gauzes can be purchased without a medical prescription for minor burns and superficial wounds.

However, for more complex conditions like skin ulcers, official documents typically recommend using the product only under medical supervision. The regulatory status may depend on the specific Ialugen product and your location.


Q: How quickly should I expect to see any kind of change after using Ialugen?

Official guidelines do not specify a typical timeframe for when changes should first be observed in the wound.

However, regulatory documents indicate that if the wound has not healed after 10–14 days, a consultation with a healthcare professional is recommended. This timeframe is generally provided as a benchmark for monitoring progress.


Q: Is Ialugen safe for people who have sensitive skin?

Based on official product information, caution is advised for individuals with sensitive skin. Although rare, using the product, especially for long periods, has been associated with localized reactions such as itching, eczema, or reddening of the skin.

Reviewing the full list of ingredients may be helpful for those with known sensitivities.


Q: Can I use Ialugen at the same time as other topical skin treatments?

Regulatory documents advise against using Ialugen concurrently with certain other topical treatments. Specifically, combining it with proteolytic enzymes (which break down proteins) or quaternary ammonium salts is not recommended, as these substances can interact with and inactivate the active ingredients.


Q: Is it necessary to use a bandage after applying Ialugen?

Whether a bandage is needed depends on the formulation used. The official instructions for Ialugen medicated gauzes state that they must be covered with a sterile secondary dressing and secured with a suitable bandage. For the cream formulation, this requirement is not specified in the administration steps.


Q: Has Ialugen been studied in children or adolescents?

According to the official patient information, systematic scientific investigations on the use and safety of Ialugen in children and adolescents have not yet been carried out.

While the product is eligible for use in children over two months of age (based on contraindication rules), the specific evidence from trials for these age groups is limited.


Q: What should I do if I accidentally get Ialugen in my eyes?

Official warnings indicate that Ialugen should be kept out of the eyes. If the product contacts the eyes, the area is typically rinsed with water for removal.


Q: What is the concentration of the active ingredient in Ialugen?

The active ingredient in Ialugen cream is sodium hyaluronate. Official documents state that the cream contains 2 mg of sodium hyaluronate per 1 g of cream.


Q: What are the differences between the cream, ointment, and gauze forms of Ialugen?

Ialugen is primarily available as a cream and as sterile medicated gauzes. Official documents detail different administration methods for these two forms, such as the need for a secondary dressing with the gauzes.

There is no official 'ointment' form typically listed in the main product range.


Q: Is the sensation of warmth after application normal when using Ialugen?

Official regulatory information does not list warmth as a normal sensation during use. A burning sensation is documented as a potential, though very rare, side effect.

This suggests that any unusual feeling of warmth or stinging is not an expected part of the application process.


Q: Does Ialugen interact with common household cleaning products?

Regulatory information warns that certain components found in common household cleaning products, specifically quaternary ammonium salts (a type of disinfectant), should be avoided. These substances can interact with and inactivate the sodium hyaluronate component of the medicine.


Q: Is there any research on Ialugen's effect on scar formation?

Official product descriptions state that the medicine is indicated to accelerate scarring. Furthermore, research summaries indicate the product may help prevent the formation of abnormal scars, such as hypertrophic and keloid scars, by supporting the organization of new tissue.


Q: Does sun exposure affect the use of Ialugen?

Official warnings advise patients to avoid direct sunlight when using the product. This recommendation is in place to minimize potential issues related to increased skin sensitivity while the medicine is applied.


Q: Is Ialugen a steroid?

No, Ialugen is not classified as a steroid. According to its official classification, it is categorized as a wound healing agent and a tissue regenerator.


Q: How long can I continuously use Ialugen according to package information?

The recommended duration of use is not a fixed number of days but is instead tied directly to the healing process itself.

Official instructions advise continuous use until satisfactory healing or scarring has taken place.


Q: Is it normal if Ialugen stings slightly when applied to damaged skin?

Stinging is not described as a normal or expected sensation in official documents. A burning sensation is specifically listed as a potential side effect, albeit a very rare one.


Q: Does Ialugen contain parabens or other preservatives?

Yes, the cream formulation of Ialugen does contain specific preservatives to maintain product stability. These ingredients include sorbic acid, propyl parahydroxybenzoate, and methyl parahydroxybenzoate.


Q: Can Ialugen be applied over makeup?

The instructions for use require the wound and the surrounding area to be cleaned and disinfected before the application of Ialugen.

This essential preparatory step implies that any substances applied to the skin, including cosmetics or makeup, must be removed prior to using the medicine.

How should Ialugen be stored and disposed of?

The storage and disposal of Ialugen must strictly follow the official instructions provided by regulatory authorities to ensure product stability and environmental safety.

Storage Requirements

The product must be stored at room temperature, generally defined as a temperature below 25°C (77°F). It is critical that the product must not be frozen or exposed to excessive heat, as this can compromise its consistency and effectiveness. The container must be kept in its original packaging and should be protected from light and stored in a dry place.

For multi-use containers, the product must be used within a limited time after opening, typically within 6 months, and must not be used after the expiry date shown on the label. The container must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Ialugen must not be disposed of in household waste or flushed down wastewater drains. For safe environmental handling, the product should be returned to a pharmacy or designated collection site, in accordance with local, regional, and national pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ialugen found in:

A-Z Index: